US stocks: Summit shares drop after US FDA declines to approve lung cancer drug

Detailed summary
Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials. Despite Summit's emphasis on regional survival differences, analysts worry that this decision could have repercussions for similar treatments in development.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Opening of the article, excerpted from The Economic Times. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (economictimes.indiatimes.com)


